Autres langues BioNTech SE Boerse Muenchen

Actions

22UA

US09075V1026

Recherche biotechnologique et médicale

Temps réel Boerse Muenchen 16:00:13 14/08/2026			Varia. 5j.	Varia. 1 janv.
78,60 ^EUR	-1,50%		+0,63%	-1,85%

11/08	Tango Therapeutics : creusement de la perte nette au deuxième trimestre	MT
06/08	Les actions européennes cotées aux États-Unis sous forme d'ADR s'inscrivent en hausse lors de la séance de jeudi	MT

Autres langues

11/08	Tango Therapeutics Q2 Net Loss Widens
06/08	European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading
04/08	Bernstein belässt Biontech auf 'Market-Perform' - Ziel 96 Dollar
04/08	European Stocks Close Higher Tuesday on Earnings Strength, Hormuz Talks
04/08	BioNTech : Q2 miss, followed by a sales guidance downgrade
04/08	BioNTech SE Announces CEO Changes
04/08	BioNTech SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Weniger Impfstoffnachfrage: Biontech tief in Verlustzone
04/08	Wall Street Bets on the Magnificent Seven Again
04/08	Pfizer hebt Prognose an und verschärft Sparkurs
04/08	Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
04/08	BioNTech : Q2 2026 Finanzbericht
04/08	BioNTech : BNTX Q2 2026 Exhibit 99.1 (Quarterly Report)
04/08	BioNTech Lowers FY26 Revenue Guidance
04/08	BioNTech's Q2 Adjusted Loss Widens, Revenue Declines; 2026 Revenue Outlook Lowered
04/08	(BNTX) BioNTech Expects 2026 Revenue Range 1.60B Euros - 1.90B Euros, vs. FactSet Est of 2.16B Euros
04/08	Earnings Flash (BNTX) BioNTech Posts Q2 Revenue 223.7M Euros, vs. FactSet Est of 157.8M Euros
04/08	Earnings Flash (BNTX) BioNTech Posts Q2 Adjusted Loss 2.22 Euros a Share, vs. FactSet Est of 1.99 Euros Loss
04/08	BioNTech senkt Prognose - Volle Impfstofflager in Deutschland belasten
04/08	BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
04/08	BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
04/08	BioNTech veröffentlicht Ergebnisse für das zweite Quartal 2026 sowie Informationen zur Geschäftsentwicklung
04/08	BioNTech SE Revises Earnings Guidance for the Financial Year 2026
04/08	MORNING BRIEFING - Deutschland/Europa
04/08	TAGESVORSCHAU/Dienstag, 4. August 2026